President Donald Trump has directed his administration to accelerate the review process for certain psychedelic substances, including ibogaine—a drug that has recently gained attention among military veterans and some conservative policymakers, despite ongoing concerns about its safety.
Ibogaine, along with other psychedelic compounds, is currently classified under the federal government’s most restrictive category for controlled substances. This classification places it among drugs considered to have a high risk of abuse and no accepted medical use. However, the administration is now taking steps to loosen some of these restrictions, with the goal of encouraging scientific research and exploring potential medical applications.
Speaking as he signed the executive order, Trump emphasized the potential benefits for people struggling with severe mental health conditions. “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” he said. He also noted that the initiative is designed to “dramatically accelerate” access to experimental treatments. “If these turn out to be as good as people are saying, it’s going to have a tremendous impact,” he added.
Supporters of ibogaine have long argued that it may offer promising results for conditions that are difficult to treat with conventional therapies. These include post-traumatic stress disorder, opioid addiction, and severe depression. The drug is derived from a plant native to West Africa and has traditionally been used in spiritual ceremonies. In recent years, it has attracted attention from veterans who claim it has helped them cope with trauma after other treatments failed.
Trump’s decision aligns with previous statements from health officials who have expressed interest in expanding access to psychedelic therapies. The issue has drawn unusual bipartisan support, with advocates from across the political spectrum calling for more research and fewer regulatory barriers.
During the signing of the order, Trump was joined by several prominent figures, including health officials, media personalities, and military veterans. Among them was Marcus Luttrell, a former Navy SEAL, who credited ibogaine with having a transformative effect on his life. “You’re going to save a lot of lives through it,” he told the president. “It absolutely changed my life for the better.”
The move also includes new steps by the Food and Drug Administration aimed at speeding up the evaluation process for certain psychedelic substances. The agency plans to introduce a system of priority review vouchers, which would allow selected drugs to move through the approval process much faster than usual. In some cases, review timelines could be reduced from several months to just a few weeks.
In addition, regulators are preparing to allow the first human clinical trials of ibogaine within the United States. This marks a significant shift, as research on the drug has historically been limited due to safety concerns. In the 1990s, government-funded studies were discontinued after findings suggested that ibogaine could cause serious heart-related complications.
Experts in the field of psychedelic research have responded cautiously. Frederick Barrett, who directs a research center focused on psychedelics, acknowledged both the potential and the risks. “It’s been incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity,” he explained. “If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others.”
Currently, no psychedelic drug has been fully approved for medical use in the United States. However, several substances—including psilocybin, MDMA, and LSD—are being studied in clinical trials for their potential to treat mental health conditions. Despite this research, all remain classified as illegal under federal law.
At the state level, some changes have already begun. Oregon and Colorado have taken steps to legalize certain forms of psychedelic therapy, particularly involving psilocybin. Meanwhile, Texas has allocated $50 million to support ibogaine research, following advocacy from veterans’ groups and political leaders.
Advocates believe the federal government’s new direction could encourage more states to invest in similar programs. “The stigma around Schedule I drugs is significant,” said one expert involved in early research efforts. “It feels like this would give pretty substantial cover for Republican governors and legislatures to step into the ring in terms of funding research programs at their universities.”
Still, the risks associated with ibogaine remain a serious concern. Medical literature has linked the drug to irregular heart rhythms and more than 30 reported deaths. Because of this, clinics that administer ibogaine—often located outside the United States—typically require intensive monitoring, including cardiac supervision and emergency preparedness.
Some providers say the executive order will not lead to immediate changes in access or affordability. “There will be no insurance coverage, it will still be considered unapproved and non-covered care,” said one clinic operator. “But what it does mean is that ibogaine shifts from being fringe and underground to being federally acknowledged.”
Recent small-scale studies have shown promising results, particularly among veterans treated abroad. In one study, participants reported improvements in symptoms such as PTSD, depression, and anxiety. However, researchers caution that these findings are preliminary, as many studies lack control groups and larger sample sizes.
Ultimately, the administration’s decision represents a significant shift in how psychedelic substances are viewed at the federal level. While the potential benefits are drawing increased attention, the path forward will depend on careful research, regulatory oversight, and a clearer understanding of both the risks and rewards associated with these powerful compounds.
